Wall Street Bullish on Spyre Therapeutics, Inc. (SYRE) with Strong Buy Rating
The update follows Mizuho’s initiation of coverage on the stock on December 18 with an Outperform rating and a share price target of $53, where it cited potential in the company’s pipeline of anti...




